All In Biotech

Drug Trial Radar · NCT06168214

Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication

Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication: A Single-center, Randomised, Controlled Trial.

Last checked: Nov 19, 2026Latest source record: Aug 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,404 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,404

Planned (sponsor's estimate)

Start

Sep 4, 2023

Primary completion

Nov 25, 2024

Study completion Dec 25, 2024

Sponsor

Lead sponsor
Xijing Hospital of Digestive DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare eradication rates of Helicobacter pylori in patients aged 18-70 years with first infection. The main questions it aims to answer are: * Main indicators: the eradication rate of Helicobacter pylori for eradication. * Secondary indicators: symptomatic relief rate at 2 weeks after treatment and 4 weeks after the end of treatment; compliance and adverse reactions during treatment.

Conditions

  • the Eradication Rates of Helicobacter Pylori

Interventions

  • Rabeprazloe+bismuth+amoxicillin+clarithromycinDrug

    PBAC: 14D: PPI: Rabeprazole 10mg bid; B: bismuth potassium citrate240mg bid/ colloidal bismuth pectin 300mg bid/ colloidal bismuth tartrate 220mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.

  • Vonoprazan+amoxicillin+clarithromycin 14 daysDrug

    VAC14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.

  • Vonoprazan+amoxicillin+clarithromycin 7 daysDrug

    VAC7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.

  • Vonoprazan+tetracycline+furazolidone 14 daysDrug

    VTF14: 14D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.

  • Vonoprazan+tetracycline+furazolidone 7 daysDrug

    VTF7: 7D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.

  • Vonoprazan+amoxicillin+furazolidone 7 daysDrug

    hVAF: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; F: furazolidone 100mg bid.

  • Vonoprazan+amoxicillin+tetracycline 14 daysDrug

    hVAT: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; T: tetracycline 500mg tid.

  • Vonoprazan+amoxicillin 7 daysDrug

    hVA7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.

  • Vonoprazan+amoxicillin 14 daysDrug

    hVA14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Eradication rate of Helicobacter pyloriTime frame: Helicobacter pylori eradication rate assessed 4-8 weeks after completion of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ying han

    Xi'an, Shaanxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.